Illumina (ILMN) Stock
Leading DNA sequencing provider powering genomic research. Here's the price, business snapshot, and what's worth knowing about Illumina in August 2026.
Illumina Inc (ILMN) is a leading provider of DNA sequencing and genotyping systems, reagents and software used by academic, clinical and commercial customers worldwide. Its platforms power genomic research, diagnostics, oncology profiling and prenatal testing, linking instrument sales with recurring consumable revenue. Key growth drivers include rising demand for personalised medicine, falling sequencing costs and expansion of clinical sequencing programmes. Investors should note significant risks: intense competition, evolving regulation for diagnostic use, patent and legal disputes, and revenue sensitivity to research funding cycles. With a market capitalisation around $15.2bn, Illumina is a growth-oriented business that can offer exposure to the structural trend of genomics but can also experience volatility and periodic setbacks. This summary provides general, educational information only and is not personal financial advice; prospective investors should research fundamentals, consider risk tolerance and seek professional advice where appropriate.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Illumina's stock, expecting it to reach a target price of $166.15.
Financial Health
Illumina is performing well with strong profits and cash flow, indicating solid financial health.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Genomics Growth Trend
Sequencing demand is rising as research and clinical applications expand; this structural tailwind can support long-term growth, though revenue can be cyclical.
Clinical Adoption Rising
Greater use of genomics in diagnostics and oncology broadens addressable markets, but clinical regulation and reimbursement affect pace of adoption.
IP & Regulatory Factors
Patent disputes and evolving regulatory rules materially affect outlook; they can create volatility and should be monitored by interested investors.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
